Chemotherapy for Advanced Prostate Cancer

  • Mario A. Eisenberger
Conference paper
Part of the ESO Monographs book series (ESO MONOGRAPHS)


The primary modality of treatment for patients with disseminated cancer of the prostate fo-cusses on the suppression of androgenic stimulation of tumour growth. Androgen deprivation procedures of various kinds result in subjective/objective clinical benefits in the majority (70–80%) of patients with metastatic disease and, clearly, reflect some of the most effective systemic palliative treatments for solid tumours in man. Paradoxically however, the development of endocrine resistance, which is observed within a relatively predictable time frame, is an extraordinarily effective phenomenon. In prostate cancer, contrary to breast cancer, responses to second-line endocrine manipulations are uncommon, usually brief and subjective and, more important, have no impact on survival. Extensive data accumulated over the past few decades, derived from large-scale, prospective randomised trials testing various methods of androgen deprivation, have shown that the median time to progression and the median survival in cohorts of patients have consistently ranged from 12–18 months and 24–30 months, respectively [1,2]. These data also stress that the development of effective non-hormonal cytotoxic approaches is the key step in order to accomplish significant advances in the systemic treatment of this disease. Preclinical data have shown that various phenotypic changes are increasingly expressed in parallel with the development of endocrine resistance [3]. These may represent either somatic mutations from a hor-monally sensitive to an insensitive state, expansion of previously insensitive cell clones, or, most likely, both [4].


Prostate Cancer Measurable Disease Endocrine Resistance Nitrogen Mustard Estramustine Phosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Byar DP: The Veterans Administration Cooperative Urological Research Group’s studies of cancer of the prostate. Cancer 1973 (32):1126–1130PubMedCrossRefGoogle Scholar
  2. 2.
    The Leuprolide Study Group: Leuprolide versus diethy Ist ilbe strol for metastatic prostatic cancer. N Engl J Med 1984 (311):1281–1286CrossRefGoogle Scholar
  3. 3.
    Isaacs JT, Isaacs WB et al: Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancer. The Prostate 1986 (9):261–281PubMedCrossRefGoogle Scholar
  4. 4.
    Isaacs JT, Coffey DS: Adaptation versus selection on the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981 (41):5070–5075PubMedGoogle Scholar
  5. 5.
    Slack NH, Mittleman A, Brady MF, Murphy GP, and investigators in the National Prostatic Cancer Project: The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer. Cancer 1980 (46):2393–2402PubMedCrossRefGoogle Scholar
  6. 6.
    O’Bryan RM, Luce JK, Talley RW, Gottlieb JF, Baker L, Bonadonna G: Phase II evaluation of adriamycin in human neoplasia. Cancer 1973 (32):1–8PubMedCrossRefGoogle Scholar
  7. 7.
    O’Bryan RM, Baker LH, Gottlieb JF, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B: Dose-response evaluation of adriamycin in human neoplasia. Cancer 1977 (39):1940–1948PubMedCrossRefGoogle Scholar
  8. 8.
    Scher H, Yagoda A, Watson R, Serber M, Whitmore W: Phase II trial of adriamycin in bidimensionally measurable prostatic adenocarcinoma. J Urol 1984 (13):1099–1102Google Scholar
  9. 9.
    Torti F, Aston D, Lum BL, Kohler M, Williams R, Spaulding JT, Shortliffe LD, Freiha FS: Weekly doxorubicin in endocrine refractory carcinoma of the prostate. J Clin Oncol 1983 (1/8):477–482Google Scholar
  10. 10.
    Merrin C: Treatment of genitourinary tumors with cis-dichloro diamine platinum (II). Experience in 250 patients. Cancer Treat Rep 1979 (63):1578–1589Google Scholar
  11. 11.
    Rossof AH, Talley RW, Stephens R, Thigpen T, Samson M, Groppe C, Eyre HJ, Eisher R: Phase II evaluation of cis-dichloro diamine platinum (II) in advanced malignancies of the genitourinary and gynecological organs: A Southwest Oncology Group Study. Cancer Treat Rep 1979 (63):1557–1564PubMedGoogle Scholar
  12. 12.
    Yagoda A, Watson RC, Natale RB, Barzell W, Sogani P, Grabstald H, Whitmore W: A critical analysis of response criteria in patients with prostatic cancer treated with cisdiaminedichloro platinum II. Cancer 1979(4):1553–1562CrossRefGoogle Scholar
  13. 13.
    Oazi R, Khandekar J: Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group Study. Am J Clin Oncol (CCT) 1983 (6):203–205CrossRefGoogle Scholar
  14. 14.
    Scott WW, Gibbons RP, Johnson DE, Prout GR, Schmidt JD, Saroff J, Murphy GP: The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J Urol 1976 (116):211–213PubMedGoogle Scholar
  15. 15.
    Murphy GP, Gibbons RP, Johnson DE, Loening SA, Prout GR, Schmidt JD, Bross DS, Chu TM, Gaeta J, Saroff J: A comparison of estramustine phosphate and streptozotocin in patients with prostatic carcinoma who had extensive irradiation. J Urol 1977(118):288–291PubMedGoogle Scholar
  16. 16.
    Eisenberger M, Simon R, O’Dwyer P, Wittes R, Friedman M: A re-evaluation of non-hormonal cytotoxic chemotherapy in treatment of prostatic carcinoma. J Clin Oncol 1985 (3):827–841PubMedGoogle Scholar
  17. 17.
    Isaacs JT: The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer.Google Scholar
  18. 18.
    Murphy GP, Beckley S, Brady MF, Chu M, Dekernion J, Dhabuwala C, Gaeta JF, Gibbons RP and NRCP investigators: Treatment of newly diagnosed prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983 (51):1264–1277PubMedCrossRefGoogle Scholar
  19. 19.
    Gibbons RP, Beckley S, Brady MF, Chu TM, Dekernion JB, Dhabuwala C, Gaeta FJ, Leoning SA, McKiel CR, McLeod DG, Pontes JE, Prout GR, Scardino PT, Schlegel IV, Schmidt JU, Scott WW, Slack NJ, Soloway MS, Murphy GP: The addition of chemotherapy to hormonal therapy for treatment of patients with metastatic carcinoma of the prostate. J Surg Oncol 1983 (23):133–142PubMedCrossRefGoogle Scholar
  20. 20.
    Moore M: Chemohormonal therapy for stage D prostatic cancer. Preliminary results of a randomized trial. Am Soc Clin Oncol 1982 abstr C-461Google Scholar
  21. 21.
    Kedia KR, Kellermeyer RW: Hormonal stimulation followed by multiagent chemotherapy in advanced prostatic cancer. Cancer Chemoth Pharmacol 1982 (18):261–265Google Scholar
  22. 22.
    Manni A, Bartholomew M, Caplan R, Boucher A, Santen R, Lipron A, Harvey H, Simmonds M, White-Hershey D, Gordon R: Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 1988 (6):1456–1466PubMedGoogle Scholar
  23. 23.
    Huben RP, Murphy GP and NPCP investigators: A comparison of DES/orchiectomy with Buserelin and with methotrexate plus DES and orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate. Cancer 1988 (62):1881–1887PubMedCrossRefGoogle Scholar
  24. 24.
    Seifter E, Bunn P, Cohen M, Ihde D: A trial of combination chemotherapy followed by therapy for previously untreated metastatic carcinoma of the prostate. J Clin Oncol 1984 (4):1305–1373Google Scholar
  25. 25.
    Eisenberger MA, Abrams JS: Chemotherapy for prostatic carcinoma. Sem Urol 1988 (6):303–310Google Scholar
  26. 26.
    Yagoda A: Response in prostate cancer: An enigma. Sem Urol 1984(1):311–319Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Mario A. Eisenberger
    • 1
  1. 1.Department of Medicine and the University of Maryland Cancer CenterUniversity of Maryland Medical SystemsBaltimoreUSA

Personalised recommendations